MICROSEMI CORP - FORM 10-Q - XML - IDEA: XBRL DOCUMENT - February 8, 2012



Attached files
FileFilename
XML - IDEA: XBRL DOCUMENT - MICROSEMI CORPR30.htm
XML - IDEA: XBRL DOCUMENT - MICROSEMI CORPR46.htm
XML - IDEA: XBRL DOCUMENT - MICROSEMI CORPR24.htm
10-Q - FORM 10-Q - MICROSEMI CORPd277511d10q.htm
XML - IDEA: XBRL DOCUMENT - MICROSEMI CORPR20.htm
XML - IDEA: XBRL DOCUMENT - MICROSEMI CORPR38.htm
XML - IDEA: XBRL DOCUMENT - MICROSEMI CORPR27.htm
XML - IDEA: XBRL DOCUMENT - MICROSEMI CORPR10.htm
XML - IDEA: XBRL DOCUMENT - MICROSEMI CORPR5.htm
XML - IDEA: XBRL DOCUMENT - MICROSEMI CORPR41.htm
XML - IDEA: XBRL DOCUMENT - MICROSEMI CORPR49.htm
XML - IDEA: XBRL DOCUMENT - MICROSEMI CORPR26.htm
XML - IDEA: XBRL DOCUMENT - MICROSEMI CORPR21.htm
XML - IDEA: XBRL DOCUMENT - MICROSEMI CORPR51.htm
XML - IDEA: XBRL DOCUMENT - MICROSEMI CORPR34.htm
XML - IDEA: XBRL DOCUMENT - MICROSEMI CORPR16.htm
XML - IDEA: XBRL DOCUMENT - MICROSEMI CORPR14.htm
XML - IDEA: XBRL DOCUMENT - MICROSEMI CORPR13.htm
XML - IDEA: XBRL DOCUMENT - MICROSEMI CORPR15.htm
XML - IDEA: XBRL DOCUMENT - MICROSEMI CORPR19.htm
XML - IDEA: XBRL DOCUMENT - MICROSEMI CORPR23.htm
XML - IDEA: XBRL DOCUMENT - MICROSEMI CORPR11.htm
XML - IDEA: XBRL DOCUMENT - MICROSEMI CORPR12.htm
XML - IDEA: XBRL DOCUMENT - MICROSEMI CORPR4.htm
XML - IDEA: XBRL DOCUMENT - MICROSEMI CORPR18.htm
XML - IDEA: XBRL DOCUMENT - MICROSEMI CORPR1.htm
XML - IDEA: XBRL DOCUMENT - MICROSEMI CORPR17.htm
XML - IDEA: XBRL DOCUMENT - MICROSEMI CORPR3.htm
XML - IDEA: XBRL DOCUMENT - MICROSEMI CORPR36.htm
XML - IDEA: XBRL DOCUMENT - MICROSEMI CORPR22.htm
XML - IDEA: XBRL DOCUMENT - MICROSEMI CORPR35.htm
XML - IDEA: XBRL DOCUMENT - MICROSEMI CORPR6.htm
XML - IDEA: XBRL DOCUMENT - MICROSEMI CORPR45.htm
XML - IDEA: XBRL DOCUMENT - MICROSEMI CORPR2.htm
XML - IDEA: XBRL DOCUMENT - MICROSEMI CORPR40.htm
XML - IDEA: XBRL DOCUMENT - MICROSEMI CORPR32.htm
XML - IDEA: XBRL DOCUMENT - MICROSEMI CORPR8.htm
XML - IDEA: XBRL DOCUMENT - MICROSEMI CORPR31.htm
XML - IDEA: XBRL DOCUMENT - MICROSEMI CORPR44.htm
XML - IDEA: XBRL DOCUMENT - MICROSEMI CORPR28.htm
XML - IDEA: XBRL DOCUMENT - MICROSEMI CORPR29.htm
XML - IDEA: XBRL DOCUMENT - MICROSEMI CORPR43.htm
EXCEL - IDEA: XBRL DOCUMENT - MICROSEMI CORPFinancial_Report.xls
XML - IDEA: XBRL DOCUMENT - MICROSEMI CORPR9.htm
XML - IDEA: XBRL DOCUMENT - MICROSEMI CORPR47.htm
XML - IDEA: XBRL DOCUMENT - MICROSEMI CORPR52.htm
XML - IDEA: XBRL DOCUMENT - MICROSEMI CORPR37.htm
XML - IDEA: XBRL DOCUMENT - MICROSEMI CORPR42.htm
XML - IDEA: XBRL DOCUMENT - MICROSEMI CORPR50.htm
XML - IDEA: XBRL DOCUMENT - MICROSEMI CORPR25.htm
XML - IDEA: XBRL DOCUMENT - MICROSEMI CORPR33.htm
XML - IDEA: XBRL DOCUMENT - MICROSEMI CORPR48.htm
XML - IDEA: XBRL DOCUMENT - MICROSEMI CORPR39.htm
EX-32 - SECTION 906 CERTIFICATION OF CEO AND CFO - MICROSEMI CORPd277511dex32.htm
EX-31.2 - SECTION 302 CERTIFICATION OF CFO - MICROSEMI CORPd277511dex312.htm
EX-31.1 - SECTION 302 CERTIFICATION OF CEO - MICROSEMI CORPd277511dex311.htm
EX-10.4 - FISCAL 2012 EXECUTIVE NON-EQUITY INCENTIVE PLAN - MICROSEMI CORPd277511dex104.htm
EX-10.3 - FORM OF NOTICE OF PERFORMANCE STOCK UNIT AWARD - MICROSEMI CORPd277511dex103.htm
v2.4.0.6
ACQUISITION
3 Months Ended
Jan. 01, 2012
ACQUISITION

2. ACQUISITION

During the quarter ended January 1, 2012, we completed our acquisition of Zarlink Semiconductor, Inc. (“Zarlink”) through a wholly-owned subsidiary. Following the expiration of the previously announced offers for all of the issued and outstanding common shares (“Zarlink Shares”) and 6% unsecured, subordinated convertible debentures maturing September 30, 2012 (“Zarlink Debentures” and together with the Zarlink Shares, the “Zarlink Securities”) of Zarlink, we acquired all remaining Zarlink Shares and Zarlink Debentures through compulsory acquisitions under, respectively, the Canada Business Corporations Act and the trust indenture governing the Zarlink Debentures. Zarlink delivers world-leading, mixed-signal chip technologies for a broad range of communication and medical applications. Its core capabilities include timing solutions that manage time-sensitive communication applications over wireless and wired networks, line circuits supporting high-quality voice services over cable and broadband connections, and ultra low-power radios enabling new wireless medical devices and therapies. Serving the world’s largest original equipment manufacturers, Zarlink’s highly integrated chip solutions help customers simplify design, lower costs and reach market quickly. We sometimes refer to this division herein as “Microsemi – CMPG.”

The fair value of the identified intangible assets for the Zarlink acquisition was estimated by performing a discounted cash flow analysis using the “income” approach. This method includes a forecast of direct revenues and costs associated with the respective intangible assets and charges for economic returns on tangible and intangible assets utilized in cash flow generation. Net cash flows attributable to the identified intangible assets were discounted to their present value at a rate commensurate with the perceived risk. The projected cash flow assumptions considered contractual relationships, customer attrition, eventual development of new technologies and market competition.

The useful lives of completed technology rights are based on the number of years in which net cash flows have been projected. The useful life of backlog is estimated based upon the fulfillment period. The useful lives of customer relationships are estimated based upon the length of the relationships currently in place, historical attrition patterns and natural growth and diversification of other potential customers. The useful life of a trade name was estimated based on the period in which a benefit could be ascribed to the identified trade names.

Assumptions used in forecasting cash flows for each of the identified intangible assets included consideration of the following:

 

   

Historical performance including sales and profitability.

 

   

Business prospects and industry expectations.

 

   

Estimated economic life of asset.

 

   

Development of new technologies.

 

   

Acquisition of new customers.

 

   

Attrition of existing customers.

 

   

Obsolescence of technology over time.

Generally, the allocation of purchase prices result in an allocation to goodwill. Depending on the tax treatment of a particular acquisition, goodwill and identifiable intangible assets may not be deductible for tax purposes. The factors that contributed to a purchase price resulting in the recognition of goodwill include:

 

   

The premium paid over market capitalization immediately prior to the merger announcement.

 

   

Our belief that the merger will create a more diverse semiconductor company with expansive offerings which will enable us to expand our product offerings.

 

   

Our belief that both companies are committed to improving cost structures and that our combined efforts after the merger should result in a realization of cost savings and an improvement of overall efficiencies.

The purchase price allocation described below is preliminary. A final determination of fair values of assets acquired and liabilities assumed relating to the transaction could differ from the preliminary purchase price allocation and if material differences exist they could result in retrospective revision to the purchase price allocation.

 

The total estimated consideration as shown in the table below is preliminarily allocated to Zarlink’s tangible and intangible assets and liabilities based on their estimated fair values as of the date of the completion of the transaction. The preliminary estimated consideration is allocated as follows (in thousands):

 

Calculation of consideration:

  

Cash consideration for Zarlink Securities

   $ 623,782   

Preliminary allocation of consideration:

  

Book value of Zarlink’s net assets

     151,576   

Adjustments to historical net book value:

  

Inventories

     7,230   

Other intangible assets

     210,100   

Deferred tax liability, net

     (35,963
  

 

 

 

Adjustment to goodwill

   $ 290,839   
  

 

 

 

Identifiable intangible assets and their estimated useful lives are as follows (amounts in thousands):

 

     Asset
Amount
     Weighted
Average
Useful Life
(Years)
 

Completed technology

   $ 47,800         6   

Customer relationships

     144,600         6   

Backlog

     15,700         1   

Trade name

     2,000         2   
  

 

 

    
   $ 210,100      
  

 

 

    

We utilized the straight line method of amortization for completed technology, customer relationships and trade name and the estimated fulfillment period for backlog.

Supplemental pro forma data

The following supplemental pro forma data summarizes the results of operations for the quarters ended January 1, 2012 and January 2, 2011, as if the acquisitions we completed in 2012 and 2011 were completed as of the first day of 2011. The supplemental pro forma information presented is for illustrative purposes only and is not necessarily indicative of the financial position or results of operations that would have been realized if the transactions had been completed on the dates indicated, nor is it indicative of future operating results or financial position. Net sales and earnings for the acquisitions on a standalone basis since their acquisition dates are impracticable to determine as on the acquisition date, we began to immediately integrate these acquisitions into existing operations, engineering groups, sales distribution networks and management structure. The pro forma adjustments are based upon currently available information and certain assumptions that we believe are reasonable under the circumstances.

The supplemental pro forma data reports actual operating results, adjusted to include the pro forma effect of, among others, the impact in cost of goods sold from manufacturing profit in acquired inventory, amortization expense of identified intangible assets, timing of the impact of restructuring expenses, timing of credit facility issuance costs, foregone interest income, incremental interest expense and the related tax effect of these items. Supplemental pro forma earnings for the quarter ended January 1, 2012 were adjusted to exclude $7.2 million in cost of goods sold from manufacturing profit in acquired inventory, $6.1 million in acquisition costs and $34.0 million in credit facility refinancing costs and supplemental pro forma earnings for the quarter ended January 2, 2011 were adjusted to include these items. Supplemental pro forma data is as follows (amounts in thousands, except per share data):

 

     Quarters Ended  
     January 1,
2012
    January 2,
2011
 

Net sales

   $ 247,754      $ 266,746   

Net loss

   $ (18,258   $ (10,129

Net loss per share

    

Basic

   $ (0.21   $ (0.12

Diluted

   $ (0.21   $ (0.12 )

User Contributions:

Comment about this document or add new information about this topic:

CAPTCHA



This web site and associated pages are not associated with, endorsed by, or sponsored by MICROSEMI CORP and has no official or unofficial affiliation with MICROSEMI CORP


Based on public records. Inadvertent errors are possible.
Faqs.org does not guarantee the accuracy or timeliness of any information on this site.  Use at your own risk. This website is not associated with the SEC

Some parts © 2013 Advameg, Inc.